Jessica Zuin

This paper demonstrates a method using CD117-blocking antibody and epitope-engineered HSPCs to treat β-thalassemia without myeloablative conditioning.

This paper shows that epitope-engineered human hematopoietic stem cells are protected from CD123-targeted immunotherapy while maintaining functionality, offering a strategy for tumor-selective therapy.

The paper quantifies how enhancer-promoter interactions influence transcription through nonlinear relationships and reveals mechanisms of transcriptional control via chromosome structure.

The paper uses live-cell imaging to show that chromosomal contacts within TADs are dynamic and stabilized by CTCF and cohesin.